Coming off a successful AIM-IPO in 2015 coupled with a follow-up £22M institutional investment, Amphion Innovations’ portfolio company Motif Bio is widely seen to be on the verge of a breakthrough in the development of antibiotics designed to be effective against multi-drug resistant bacteria.
To this end, Amphion Innovations, developer of medical, life science and technology businesses, has today announced receipt of a funding of $1.8M, co-led by RiverFort Global Capital, which provides capital to support the growth of Motif Bio going forward, as well as progress other portfolio business pipelines through development stages.
The investment marks the commencement of a relationship between RiverFort and Amphion as the company continues to help build shareholder value in its high growth company portfolio in the US and UK.
Comments